NeoGenomics operates a network of cancer-focused diagnostic laboratories offering genetic, molecular, and pathology testing used to diagnose tumors and guide treatment decisions. It serves oncologists, hospitals, and reference labs, and also provides specialty testing and pharma services that support oncology drug development and clinical trials. The business is built around complex oncology assays rather than general clinical chemistry.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 181.3 | — | -45.1 | — |
| Q3 2025 | 187.8 | — | -27.1 | — |
| Q4 2025 | 190.2 | — | -9.9 | — |
| Q1 2026 | 186.7 | — | -17.1 | — |
| Q2 2026 | 201.7 | 11.2% | 2.2 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Enterprise Financial Services Corp (EFSC), Addus HomeCare Corporation (ADUS), Vertex, Inc. (VERX), Celldex Therapeutics, Inc. (CLDX), WaFd, Inc. (WAFD), CleanSpark, Inc. (CLSK)